Oral Immunotherapy in Peanut-Allergic Adults Using Real-World Materials.

ABSTRACT:

Background

Peanut oral immunotherapy (OIT) has shown effectiveness in achieving desensitization of children; however, evidence in adults is lacking.

Methods

This phase II trial evaluated peanut OIT in peanut-allergic adults using real-world peanut products. A Simon's minimax two-stage design, incorporating a stop:go for futility, was employed. A separate untreated control group was also recruited for comparison of mechanistic parameters. Participants underwent baseline double-blind placebo-control food challenges (DBPCFC) with peanut protein doses of 0.3 to 300 mg. Reacting participants were initiated on daily OIT with 2-weekly updosing until reaching a maintenance dose of 1000 mg (four large peanuts). The primary outcome was the proportion of OIT participants who tolerated

SUBMITTER: Hunter H 

PROVIDER: S-EPMC12368739 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature